ArticleACS biomaterials science & engineering2025
Small Extracellular Vesicles Released from ARPE-19 Cells Grown under Diabetic Retinopathy Conditions Promote NLRP3 Inflammasome Activation.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is a multiprotein complex that forms part of the innate immune system. Recent studies have shown that the inflammasome pathway is upregulated in diabetic retinopathy (DR), resulting in breakdown of the retinal pigment epithelium (RPE) barrier. It has been hypothesized that small extracellular vesicles (sEVs) may transport inflammasome-related cargo between cells, which in turn contributes to the DR pathogenesis. The aim of this study was to investigate whether sEVs released from ARPE-19 cells grown under basal, DR-like conditions, and DR-like conditions with Peptide 5 treatment differ in inflammasome cargo and uptake. Additionally, the effects of the released sEVs on inflammasome activation in ARPE-19 cells, as well as their effect on vascular growth in a choroidal explant model, were investigated. Results demonstrated that sEVs from ARPE-19 cells grown under DR-like conditions carried increased inflammasome-related cargo and promoted NLRP3 inflammasome activation in recipient cells and tissues. Conversely, sEVs released from cells grown under basal and DR-like conditions with Peptide 5 treatment carried less inflammasome-related cargo. This research provides insights into the role of sEVs in the DR pathogenesis and suggests the potential therapeutic use of certain sEVs in treating DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.